159 related articles for article (PubMed ID: 29560976)
1. The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs - an HPLC-ICP-MS study.
Theiner S; Grabarics M; Galvez L; Varbanov HP; Sommerfeld NS; Galanski MS; Keppler BK; Koellensperger G
Dalton Trans; 2018 Apr; 47(15):5252-5258. PubMed ID: 29560976
[TBL] [Abstract][Full Text] [Related]
2. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
Göschl S; Varbanov HP; Theiner S; Jakupec MA; Galanski MS; Keppler BK
J Inorg Biochem; 2016 Jul; 160():264-74. PubMed ID: 27055943
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.
Ritacco I; Mazzone G; Russo N; Sicilia E
Inorg Chem; 2016 Feb; 55(4):1580-6. PubMed ID: 26812023
[TBL] [Abstract][Full Text] [Related]
4. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
5. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
6. The interaction of platinum-based drugs with native biologically relevant proteins.
Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
[TBL] [Abstract][Full Text] [Related]
7. Insertion of (Bioactive) Equatorial Ligands into Platinum(IV) Complexes.
Kastner A; Schueffl H; Yassemipour PA; Keppler BK; Heffeter P; Kowol CR
Angew Chem Int Ed Engl; 2023 Nov; 62(46):e202311468. PubMed ID: 37703130
[TBL] [Abstract][Full Text] [Related]
8. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.
Höfer D; Varbanov HP; Legin A; Jakupec MA; Roller A; Galanski MS; Keppler BK
J Inorg Biochem; 2015 Dec; 153():259-271. PubMed ID: 26365319
[TBL] [Abstract][Full Text] [Related]
9. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
[TBL] [Abstract][Full Text] [Related]
10. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection.
Martinčič A; Cemazar M; Sersa G; Kovač V; Milačič R; Ščančar J
Talanta; 2013 Nov; 116():141-8. PubMed ID: 24148385
[TBL] [Abstract][Full Text] [Related]
11. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
12. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
13. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
Jacobs S; McCully CL; Murphy RF; Bacher J; Balis FM; Fox E
Cancer Chemother Pharmacol; 2010 Apr; 65(5):817-24. PubMed ID: 19662415
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
15. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
Sinisi M; Intini FP; Natile G
Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.
Theiner S; Kornauth C; Varbanov HP; Galanski M; Van Schoonhoven S; Heffeter P; Berger W; Egger AE; Keppler BK
Metallomics; 2015 Aug; 7(8):1256-64. PubMed ID: 25856224
[TBL] [Abstract][Full Text] [Related]
17. A shotgun approach for the identification of platinum-protein complexes.
Moraleja I; Moreno-Gordaliza E; Esteban-Fernández D; Mena ML; Linscheid MW; Gómez-Gómez MM
Anal Bioanal Chem; 2015 Mar; 407(9):2393-403. PubMed ID: 25618759
[TBL] [Abstract][Full Text] [Related]
18. The influence of the ethane-1,2-diamine ligand on the activity of a monofunctional platinum complex.
Graziotto ME; Akerfeldt MC; Gunn AP; Yang K; Somerville MV; Coleman NV; Roberts BR; Hambley TW; New EJ
J Inorg Biochem; 2017 Dec; 177():328-334. PubMed ID: 28789807
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
20. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
